Back to search

Article

PHGDH inhibition overcomes dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinoma

2025-07-14

Abstract excerpt

<title>Abstract</title> <p>Dabrafenib, a BRAF kinase inhibitor, is used clinically to treat anaplastic thyroid carcinoma (ATC) harboring the BRAF V600E mutation. However, its clinical efficacy is limited due to the rapid emergence of resistance to treatment. In this study, we established a dabrafenib-resistant ATC cell line (8505C-R) and compared its molecular and phenotypic characteristics with those of the pare...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7cd74cc1-b17d-56be-9eeb-8b27ba589f19
DOI
10.21203/rs.3.rs-7069883/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PHGDH inhibition overcomes dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinomaDOI 10.21203/rs.3.rs-7069883/v1
Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancerSemantic proximity
Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.Semantic proximity
POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation.Semantic proximity
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity
CRISPR-Based Gene Dependency Screens reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid CancerSemantic proximity
Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Semantic proximity
Dual targeting of PDPK1 and BRAF V600E is synthetically lethalSemantic proximity
A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer PatientSemantic proximity
Fatty acid oxidation drives Acetyl-CoA-dependent H3K9ac reprogramming to promote adaptive resistance to BRAFV600E inhibition in thyroid cancerSemantic proximity
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.Semantic proximity
Select a neighboring publication to make it the new centre.